

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

99 AUG 16 PM 4:16

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

H.D.

1. Registrant Name Genentech, Inc.			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 808 17th Street, NW Suite 250 City Washington State/Zip (or Country) DC 20006 USA			
3. Principal Place of Business (if different from line 2) City S. San Francisco State/Zip (or Country) CA 94080 USA			
4. Contact Name Walter Moore		Telephone	5. Senate ID # 15920-12
7. Client Name <input type="checkbox"/> Self Self		E-mail (optional)	6. House ID # 31464000

TYPE OF REPORT 8. Year 1999 Midyear (January 1-June 30) ☒ OR Year End (July 1-December 31) ☐

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ >> Termination Date _____

11. No Lobbying Activity ☐

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input type="checkbox"/> >> \$ _____ Income (nearest \$20,000)	\$10,000 or more <input checked="" type="checkbox"/> >> \$ \$520,000.00 Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options. <input type="checkbox"/> Method A. Reporting amounts using LIDA definitions only <input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature _____ Date 08/16/1999

Printed Name and Title Walter Moore - Vice President, Government Affairs Page 1 of 10

Registrant Name: Genentech, Inc.

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying Issues

H.R.1906, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2000, Title 6, provisions that relate to the FDA budget.

S.1233, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2000, Title 6, provisions that relate to the FDA budget.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Moore, Walter</u>		<u>No</u>
<u>Wagner, Heidi</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date 08/16/1999

Printed Name and Title Walter Moore - Vice President, Government Affairs

Page 2 of 10

Registrant Name: Genentech, Inc.

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues

H.R.1907, American Inventors Protection Act of 1999, All provisions as they relate to reform of the patent system.
Patent procedure (no specific legislation).

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

Department of Commerce
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Moore, Walter</u>		<u>No</u>
<u>Wagner, Heidi</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above

☐ Check if None

Roche Holding Ltd None

Signature _____

Date 08/16/1999

Printed Name and Title Walter Moore - Vice President, Government Affairs

Page 3 of 10

Registrant Name: Genentech, Inc.

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

H.R.10, Financial Services Act of 1999, Provisions relating to medical confidentiality.

H.R.1057, Medical Information Privacy and Security Act, All provisions as they relate to medical records confidentiality.

H.R.1941, Health Information Privacy Act, All provisions as they relate to medical records confidentiality.

H.R.306, Genetic Information Nondiscrimination in Health Insurance Act of 1999, All provisions as they relate to genetic discrimination.

H.R.448, Patient Protection Act of 1999, All provisions as they relate to genetic information discrimination.

S.326, Patients' Bill of Rights Act, All provisions as they relate to genetic information discrimination.

S.543, Genetic Information Nondiscrimination in Health Insurance Act of 1999, All provisions as they relate to genetic discrimination.

S.573, Medical Information Privacy and Security Act, All provisions as they relate to medical records confidentiality.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

Department of Health & Human Services

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Moore, Walter		No
Wagner, Heidi		No

19. Interest of each foreign entity in the specific issues listed on line 16 above

☐ Check if None

Roche Holding Ltd None

Signature _____ Date 08/16/1999

Printed Name and Title Walter Moore - Vice President, Government Affairs Page 4 of 10

Client Name: Self

Page 5 of 10

Registrant Name: Genentech, Inc.

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

H.R.1495, Access to Prescription Medications in Medicare Act of 1999, All provisions as they relate to the creation of a Medicare drug benefit.

H.R.664, Prescription Drug Fairness for Seniors Act of 1999, All provisions as they relate to the creation of a Medicare drug benefit.

S.731, Prescription Drug Fairness for Seniors Act of 1999, All provisions as they relate to the creation of a Medicare drug benefit.

S.841, Access to Rx Medications in Medicare Act of 1999, All provisions as they relate to the creation of a Medicare drug benefit.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Moore, Walter		No
Wagner, Heidi		No

19. Interest of each foreign entity in the specific issues listed on line 16 above

☐ Check if None

Roche Holding Ltd None

Signature _____ Date 08/16/1999

Printed Name and Title Walter Moore - Vice President, Government Affairs Page 6 of 10

Registrant Name: Genentech, Inc.

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code SCI (one per page)

16. Specific Lobbying issues

S.296, Federal Research Investment Act, All provisions as they relate to federal research investments.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Moore, Walter</u>		<u>No</u>
<u>Wagner, Heidi</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above

☐ Check if None,

Roche Holding Ltd None

Signature _____ Date 08/16/1999

Printed Name and Title Walter Moore - Vice President, Government Affairs Page 7 of 10

Registrant Name: Genentech, Inc.

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific Lobbying issues

H.R.1039, To amend the Internal Revenue Code of 1986 to provide for a medical innovation tax credit for clinical testing research expenses attributable to academic medical centers and other qualified., All provisions as they relate to the medical innovation tax credit.

H.R.760, To amend the Internal Revenue Code of 1986 to permanently extend the research credit, All provisions as they relate to the extension of the research and development tax credit.

H.R.835, To amend the Internal Revenue Code of 1986 to permanently extend the research credit and to adjust the alternative incremental credit rates, All provisions as they relate to the extension of the research and development tax credit.

S.195, To amend the Internal Revenue Code of 1986 to permanently extend the research credit, All provisions as they relate to the extension of the research and development tax credit.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Moore, Walter		No
Wagner, Heidi		No

19. Interest of each foreign entity in the specific issues listed on line 16 above

☐ Check if None

Roche Holding Ltd None

Signature _____ Date 08/16/1999

Printed Name and Title Walter Moore - Vice President, Government Affairs Page 8 of 10

Registrant Name: Genentech, Inc.

Client Name: Self

Item	Description	Data
16	Lobbying Issues	S.1010, To amend the Internal Revenue Code of 1986 to provide for a medical innovation tax credit for clinical testing research expenses attributable to academic medical centers and other qualified... All provisions as they relate to the medical innovation tax credit.
16	Lobbying Issues	S.680, To amend the Internal Revenue Code of 1986 to permanently extend the research credit, and for other purposes, All provisions as they relate to the extension of the research and development tax credit.

Registrant Name: Genentech, Inc.

Client Name: Self

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different from line 20)

City _____ State/Zip (or Country) _____

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that no longer pertain

GOV, MAN

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES


27. Add the following foreign entities

Name	Address	Principal Place of Business (city and state or country)	Amount of contribution for lobbying activities	Ownership % in client
Roche Holding Ltd	c/o F. Hoffmann La Roche AG Basel CH-1002 Switzerland		\$0.00	81.00%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client, or affiliated organization

Roche Holding Ltd

Signature



Date 08/16/1999

Printed Name and Title Walter Moore - Vice President, Government Affairs

Page 10 of 10